AR057661A1 - Un derivado de oxima y sus preparaciones - Google Patents
Un derivado de oxima y sus preparacionesInfo
- Publication number
- AR057661A1 AR057661A1 ARP060102967A ARP060102967A AR057661A1 AR 057661 A1 AR057661 A1 AR 057661A1 AR P060102967 A ARP060102967 A AR P060102967A AR P060102967 A ARP060102967 A AR P060102967A AR 057661 A1 AR057661 A1 AR 057661A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- heteroaryl
- hydrogen atom
- halogen atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
El problema de la presente es proveer un compuesto util como un agente activador de glucoquinasa, que es el derivado de oxima de la formula (1), se divulgan derivados de oxima, un método para su preparacion e intermediarios. Estos compuestos ejercen un efecto de activacion de la glucoquinasa, siendo al parecer utiles para tratar la diabetes tipo II. Reivindicacion 1: Un activador de glucoquinasa caracterizado porque comprende un compuesto de la formula general (1), en donde el Anillo A es arilo o heteroarilo; Q es cicloalquilo, heterociclo, alquilo o alquenilo; Anillo T es heteroarilo o heterociclo; R1 es un átomo de hidrogeno, átomo de halogeno, cicloalquilsulfonilo, alquilsulfonilo, alquilsulfinilo, alquiltio, o tetrazolilo sustituido o no sustituido; R2 es un átomo de hidrogeno, átomo de halogeno, cicloalquilsulfonilo, alquilsulfonilo sustituido o no sustituido, alquiltio sustituido o no sustituido, nitro, amino sustituido o no sustituido, aminosulfonilo sustituido o no sustituido, heterociclil-tio sustituido o no sustituido, heterociclil-sulfonilo sustituido o no sustituido, heterociclil-sulfonilo sustituido o no sustituido, heteroarilsulfonilo sustituido o no sustituido, alqueniloxi, alcoxi sustituido o no sustituido, alquilsulfinilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, heteroariltio sustituido o no sustituido; R3 y R4 son, de modo independientemente, un átomo de hidrogeno, alcoxi, heterociclo sustituido o no sustituido, heteroarilo sustituido o no sustituido, alcoxialcoxi, cicloalquilo sustituido o no sustituido, ciano, arilo sustituido o no sustituido, carbamoilo sustituido o no sustituido, hidroxi, alcanoilo, alquiltio, alcoxicarbonilo, ariloxi sustituido o no sustituido, átomo de halogeno, oxo, o arilcarboniloxi sustituido o no sustituido; R5 es átomo de hidrogeno, formilo, átomo de halogeno, oxo, alcoxi sustituido o no sustituido, aminosulfonilo sustituido o no sustituido, alquiltio sustituido o no sustituido, ciano, heterociclilsulfonilo sustituido o no sustituido, nitro, cicloalquilo sustituido o no sustituido, alcoxicarbonilo, alquenilo, alquilsulfonilo, carbamoilo sustituido o no sustituido, heteroariltio sustituido o no sustituido, amino sustituido o no sustituido, carboxilo, heteroarilo sustituido o no sustituido, alquinilo sustituido o no sustituido, heterociclil-carbonilo sustituido o no sustituido, heterociclil-oxi sustituido o no sustituido, heterociclo sustituido o no sustituido, heterocicliltio sustituido o no sustituido, cicloalquiloxi sustituido o no sustituido, alcanoilo, o alquilo sustituido o no sustituido; R6 es átomo de hidrogeno, alquilo sustituido o no sustituido, un átomo de halogeno, o carboxilo; o una de sus sales farmacéuticamente aceptable como un ingrediente activo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005202014 | 2005-07-11 | ||
JP2006114243 | 2006-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR057661A1 true AR057661A1 (es) | 2007-12-12 |
Family
ID=37388432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060102967A AR057661A1 (es) | 2005-07-11 | 2006-07-10 | Un derivado de oxima y sus preparaciones |
Country Status (16)
Country | Link |
---|---|
US (2) | US7514439B2 (es) |
EP (1) | EP1907387A1 (es) |
JP (1) | JP4033409B1 (es) |
KR (1) | KR100965040B1 (es) |
CN (1) | CN101218237B (es) |
AR (1) | AR057661A1 (es) |
AU (1) | AU2006267387B2 (es) |
BR (1) | BRPI0613451A2 (es) |
CA (1) | CA2613303C (es) |
IL (1) | IL188258A0 (es) |
MX (1) | MX2008000560A (es) |
NO (1) | NO20080717L (es) |
NZ (1) | NZ564743A (es) |
RU (1) | RU2420525C2 (es) |
TW (1) | TWI359149B (es) |
WO (1) | WO2007007886A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2420525C2 (ru) * | 2005-07-11 | 2011-06-10 | Мицубиси Танабе Фарма Корпорейшн | Производные оксимов и их получение |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP2261216A3 (en) | 2006-07-24 | 2011-12-14 | F. Hoffmann-La Roche AG | Pyrazoles as glucokinase activators |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
JP2010509237A (ja) * | 2006-11-02 | 2010-03-25 | アレテ セラピューティクス, インコーポレイテッド | 可溶性エポキシドヒドロラーゼ阻害剤 |
US7902248B2 (en) * | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
WO2008084873A1 (ja) * | 2007-01-10 | 2008-07-17 | Mitsubishi Tanabe Pharma Corporation | オキシム誘導体 |
EP2105435A4 (en) * | 2007-01-10 | 2011-06-15 | Mitsubishi Tanabe Pharma Corp | Hydrazone derivatives |
JP5323063B2 (ja) * | 2007-05-31 | 2013-10-23 | 塩野義製薬株式会社 | オキシイミノ化合物およびその使用 |
US8304557B2 (en) | 2007-06-05 | 2012-11-06 | Takeda Pharmaceutical Company Limited | Fused heterocycle derivatives and use thereof |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
JP5270553B2 (ja) | 2007-08-23 | 2013-08-21 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
KR20100113518A (ko) | 2008-01-18 | 2010-10-21 | 아스텔라스세이야쿠 가부시키가이샤 | 페닐아세트아미드 유도체 |
WO2009099080A1 (ja) * | 2008-02-06 | 2009-08-13 | Daiichi Sankyo Company, Limited | 新規フェニルピロール誘導体 |
US7741327B2 (en) | 2008-04-16 | 2010-06-22 | Hoffmann-La Roche Inc. | Pyrrolidinone glucokinase activators |
US8258134B2 (en) | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
AR074619A1 (es) | 2008-04-28 | 2011-02-02 | Teijin Pharma Ltd | Derivados de ciclopentilacrilamida |
MX2010012298A (es) | 2008-05-16 | 2011-03-15 | Takeda San Diego Inc | Activadores de glucocinasa. |
EP2346820B1 (en) | 2008-06-11 | 2013-02-13 | Shionogi & Co., Ltd. | Oxycarbamoyl compounds and the use thereof |
TW201014822A (en) | 2008-07-09 | 2010-04-16 | Sanofi Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
WO2010064611A1 (ja) | 2008-12-01 | 2010-06-10 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
UA104742C2 (uk) | 2008-12-19 | 2014-03-11 | Эли Лилли Энд Компани | Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази |
CN102482312A (zh) | 2009-08-26 | 2012-05-30 | 赛诺菲 | 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途 |
US8222416B2 (en) | 2009-12-14 | 2012-07-17 | Hoffmann-La Roche Inc. | Azaindole glucokinase activators |
WO2011093423A1 (ja) * | 2010-01-29 | 2011-08-04 | 田辺三菱製薬株式会社 | (e)-ヒドロキシイミノフェニル酢酸誘導体の製法 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8178689B2 (en) | 2010-06-17 | 2012-05-15 | Hoffman-La Roche Inc. | Tricyclic compounds |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
US8680283B2 (en) | 2010-06-22 | 2014-03-25 | Bayer Intellectual Property Gmbh | Process for the preparation of 5-substituted 1-alkyltetrazolyl oxime derivatives |
EP2402327B1 (en) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Acetamide compounds as glucokinase activators, their process and medicinal applications |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2781521A4 (en) | 2011-10-19 | 2015-03-04 | Kowa Co | NOVEL COMPOUND OF SPIROINDOLINE AND THERAPEUTIC AGENT CONTAINING THE SAME |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1399089A (en) * | 1971-05-14 | 1975-06-25 | Glaxo Lab Ltd | Carboxylic acids and derivatives thereof |
HU172017B (hu) | 1971-05-14 | 1978-05-28 | Glaxo Lab Ltd | Sposob poluchenija 7-beta-skobka-al'fa-oksiimino-skobka zakryta-acilamido-cef-3-em-4-karbonovykh kislot, zamehhennykh efirom v pozicii oksiimino-gruppa |
GB1445979A (en) | 1972-10-25 | 1976-08-11 | Glaxo Lab Ltd | Cephalosporin derivatives |
BE791214A (fr) | 1972-05-08 | 1973-05-10 | Glaxo Lab Ltd | Procede de preparation d'isomeres de derives d'acide hydroxyiminoacetique etherifie purs |
GB1446435A (en) * | 1972-11-02 | 1976-08-18 | Cooper Ltd Ethyl | Lubricant additives |
MX4573E (es) * | 1975-10-03 | 1982-06-18 | Fujisawa Pharmaceutical Co | Procedimiento microbiologico para la produccion de nocardicina c d e f y g |
US4355172A (en) * | 1976-11-05 | 1982-10-19 | Eli Lilly And Company | Process for 4-(D-3-amino-3-carboxypropoxy)-phenylglyoxylic acid oxime derivatives |
CH632130A5 (en) * | 1977-03-02 | 1982-09-30 | Ciba Geigy Ag | Compositions on the basis of oxime ethers, oxime esters or oxime carbamates which are suitable in agriculture for crop protection |
IT1110460B (it) * | 1977-03-02 | 1985-12-23 | Ciba Geigy Ag | Prodotti che favoriscono la crescita delle piante e prodotti che proteggono le piante a base di eteri di ossime e di esteri di ossime loro preparazione e loro impiego |
GR75487B (es) * | 1981-06-22 | 1984-07-23 | Fujisawa Pharmaceutical Co | |
EP0137442A3 (de) * | 1983-10-08 | 1986-01-15 | Hoechst Aktiengesellschaft | Cephalosporinderivate und Verfahren zu ihrer Herstellung |
GB2161476B (en) | 1984-05-25 | 1988-01-27 | Toyama Chemical Co Ltd | 2-aminothiazolyl-2-methoxyimino acetamides and their use in preparing cephalosporins |
DE3686632T2 (de) * | 1985-04-30 | 1993-01-21 | Takeda Chemical Industries Ltd | Antibiotische derivate, ihre herstellung und verwendung. |
GB8617648D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Fungicides |
GB8905160D0 (en) * | 1989-03-07 | 1989-04-19 | Beecham Group Plc | Novel compounds |
US5192770A (en) * | 1990-12-07 | 1993-03-09 | Syntex (U.S.A.) Inc. | Serotonergic alpha-oxoacetamides |
US5207597A (en) * | 1991-06-21 | 1993-05-04 | Amp Incorporated | Shielded connector with dual cantilever panel grounding beam |
ES2099014B1 (es) * | 1994-03-22 | 1998-01-16 | Univ Cordoba | Nuevos eteres de oxima quirales derivados del limoneno, procedimiento para su preparacion y aplicaciones. |
CA2189573A1 (en) * | 1994-05-17 | 1995-11-23 | Ronald E. Hackler | N-(5-isothiazolyl)amide pesticides |
MX9705726A (es) * | 1995-01-30 | 1997-11-29 | Bayer Ag | Amidas del acido alcoximinoacetico. |
GB9602866D0 (en) * | 1996-02-13 | 1996-04-10 | Smithkline Beecham Plc | Novel process |
GB9823871D0 (en) * | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
OA12046A (en) | 1999-08-12 | 2006-05-02 | Pharmacia Italia Spa | 3(5)-Amino-pyrazole derivatives, process for theirpreparation and their use as antitumor agents. |
EP1200393B1 (en) * | 1999-08-13 | 2003-12-10 | Monsanto Technology LLC | Oxime amides and hydrazone amides having fungicidal activity |
AU763033B2 (en) | 1999-10-01 | 2003-07-10 | Japan Energy Corporation | Novel quinazoline derivatives |
WO2001034579A1 (fr) * | 1999-11-10 | 2001-05-17 | Takeda Chemical Industries, Ltd. | Derives d'acide alcoxyiminoalcanoique |
PE20010830A1 (es) * | 2000-01-28 | 2001-09-06 | Syngenta Ltd | Derivados de azol insecticidas o fungicidas y composiciones que los comprenden |
US6369232B1 (en) | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
CN1285569C (zh) * | 2001-01-23 | 2006-11-22 | 三共阿格罗株式会社 | Z-α-烷氧基亚氨基苯基乙酸衍生物的制备方法 |
ES2197001B1 (es) * | 2002-03-26 | 2004-11-16 | Laboratorios Vita, S.A. | Procedimiento de obtencion de un compuesto farmaceuticamente activo. |
EA011297B1 (ru) | 2002-04-26 | 2009-02-27 | Ф. Хоффманн-Ля Рош Аг | Замещённые фенилацетамиды и их применение в качестве активаторов глюкокиназы |
WO2004058724A1 (ja) | 2002-12-25 | 2004-07-15 | Sumitomo Chemical Company, Limited | フェニルピラゾール化合物及びそれを用いた植物病害の防除方法 |
JP4621198B2 (ja) * | 2003-02-11 | 2011-01-26 | プロシディオン・リミテッド | トリ(シクロ)置換アミドグルコキナーゼ活性化化合物 |
PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
WO2004111044A1 (en) | 2003-06-17 | 2004-12-23 | Glenmark Pharmaceuticals Ltd. | Tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation |
MXPA06002853A (es) * | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
JP2007126358A (ja) * | 2004-01-20 | 2007-05-24 | Fujiyakuhin Co Ltd | フェニルアラニン誘導体 |
RU2420525C2 (ru) * | 2005-07-11 | 2011-06-10 | Мицубиси Танабе Фарма Корпорейшн | Производные оксимов и их получение |
US7902248B2 (en) | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
-
2006
- 2006-07-10 RU RU2008104919/04A patent/RU2420525C2/ru not_active IP Right Cessation
- 2006-07-10 CN CN2006800250710A patent/CN101218237B/zh not_active Expired - Fee Related
- 2006-07-10 AR ARP060102967A patent/AR057661A1/es not_active Application Discontinuation
- 2006-07-10 AU AU2006267387A patent/AU2006267387B2/en not_active Ceased
- 2006-07-10 MX MX2008000560A patent/MX2008000560A/es active IP Right Grant
- 2006-07-10 EP EP06781142A patent/EP1907387A1/en not_active Withdrawn
- 2006-07-10 KR KR1020087000714A patent/KR100965040B1/ko not_active IP Right Cessation
- 2006-07-10 NZ NZ564743A patent/NZ564743A/en not_active IP Right Cessation
- 2006-07-10 JP JP2007528416A patent/JP4033409B1/ja not_active Expired - Fee Related
- 2006-07-10 CA CA2613303A patent/CA2613303C/en not_active Expired - Fee Related
- 2006-07-10 US US11/660,905 patent/US7514439B2/en not_active Expired - Fee Related
- 2006-07-10 TW TW095125016A patent/TWI359149B/zh not_active IP Right Cessation
- 2006-07-10 BR BRPI0613451-3A patent/BRPI0613451A2/pt not_active IP Right Cessation
- 2006-07-10 WO PCT/JP2006/314117 patent/WO2007007886A1/en active Application Filing
-
2007
- 2007-12-19 IL IL188258A patent/IL188258A0/en unknown
-
2008
- 2008-02-08 NO NO20080717A patent/NO20080717L/no not_active Application Discontinuation
- 2008-11-20 US US12/274,674 patent/US8119626B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2613303C (en) | 2012-06-19 |
EP1907387A1 (en) | 2008-04-09 |
IL188258A0 (en) | 2008-08-07 |
US7514439B2 (en) | 2009-04-07 |
US20080132479A1 (en) | 2008-06-05 |
MX2008000560A (es) | 2008-03-10 |
TWI359149B (en) | 2012-03-01 |
RU2420525C2 (ru) | 2011-06-10 |
US20090291936A1 (en) | 2009-11-26 |
CA2613303A1 (en) | 2007-01-18 |
NO20080717L (no) | 2008-04-09 |
JP4033409B1 (ja) | 2008-01-16 |
JP2008510735A (ja) | 2008-04-10 |
NZ564743A (en) | 2010-03-26 |
RU2008104919A (ru) | 2009-08-20 |
WO2007007886A1 (en) | 2007-01-18 |
BRPI0613451A2 (pt) | 2011-01-11 |
CN101218237B (zh) | 2012-03-28 |
CN101218237A (zh) | 2008-07-09 |
KR100965040B1 (ko) | 2010-06-21 |
TW200732333A (en) | 2007-09-01 |
AU2006267387B2 (en) | 2010-11-18 |
US8119626B2 (en) | 2012-02-21 |
KR20080016736A (ko) | 2008-02-21 |
AU2006267387A1 (en) | 2007-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR057661A1 (es) | Un derivado de oxima y sus preparaciones | |
AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
PE20071001A1 (es) | Derivados de 1-(azolin-2-il)-amino-1-fenil-2-hetaril-etano con actividad pesticida | |
PE20091573A1 (es) | Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa | |
PE20121127A1 (es) | Derivados de piridina y pirazina como moduladores de cinasa de proteina | |
PE20090641A1 (es) | Amidas heterociclicas | |
PE20061295A1 (es) | Derivados de acetileno | |
PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
PE20060097A1 (es) | Piridinas 2-sustituidas y procedimientos para su obtencion | |
NO20090202L (no) | Prolylhydroksylaseinhibitorer | |
CO6650337A2 (es) | Derivados de 3- hidroxi-5 -arilisotiazol novedoso | |
PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
PE20051054A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
EA200701122A1 (ru) | Потенциаторы рецепторов глутамата | |
PE20070112A1 (es) | Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos | |
PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
NO341631B1 (no) | Hydroksybenzamidderivater og deres anvendelse, fremgangsmåte for fremstilling og farmasøytiske sammensetninger | |
AR064490A1 (es) | Ciano-benzanilidas sustituidas, intermediarios para su preparacion, una composicion pesticida que las comprende y su utilizacion en un metodo para combatir plagas. | |
NO20081001L (no) | Derivater av karboksamid som antagonister for muskarinisk reseptor | |
PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
IL195877A0 (en) | Pest control agent containing novel pyridyl-methanamine derivative or salt thereof | |
PE20071090A1 (es) | 5-pirazolpiperidinas-(sustituidas) | |
UY29747A1 (es) | Concentrado emulsificable- | |
PE20142282A1 (es) | Nuevos derivados de aril-quinolina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |